How the vaginal ring for HIV prevention that has been approved for use by women above 18 in SA works

accreditation
Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
0:00
play article
Subscribers can listen to this article
The monthly dapivirine vaginal ring received regulatory approval from the South African Health Products Regulatory Authority (SAHPRA). PHOTO: Courtesy of the International Partnership for Microbicides
The monthly dapivirine vaginal ring received regulatory approval from the South African Health Products Regulatory Authority (SAHPRA). PHOTO: Courtesy of the International Partnership for Microbicides
Supplied

If you bring your index finger to your thumb then make a circle, that’s about how small this silicone ring is.

Its size is tiny but its impact enormous, which is why SAHPRA’s decision to give South Africa the regulatory go-ahead to make the dapivirine vaginal ring (DVR) available monthly to women 18 and older has been lauded by women’s health and reproductive rights advocates as seismic.

In South Africa, nearly 2 700 women aged 15 and older acquire HIV every week, according to the International Partnership for Microbicides (IPM), the nonprofit which led the SA and Uganda Phase III trials demonstrating the ring’s safety and efficacy. The decision by the South African Health Products Regulatory Authority (SAHPRA) to approve it “marks a major milestone that brings the first long-acting and woman-controlled product another step closer to reaching women”, said IPM in a press statement. 

Support independent journalism
Get 14 days free to read all our investigative and in-depth journalism. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed.
Subscribe
Already a subscriber? Sign in